Page 1 of 1

Bafiertam offers a lower dosage vs. Tecfidera

Posted: Tue Jun 30, 2020 8:26 am
by NHE
A lower dose of Bafiertam as compared to Tecfidera may lead to fewer GI side effects, but this has yet to be clinically evaluated.

https://mymsaa.org/news/bafiertam-oral- ... rms-of-ms/
Bafiertam is a “bioequivalent alternative” to Biogen’s Tecfidera® (dimethyl fumarate), which means that the active ingredient and site of action do not differ significantly between the two medications. The therapeutic effect is assumed to be equivalent. Since a lower dose of Bafiertam is equivalent to Tecfidera, this may potentially lead to a reduction in gastrointestinal (GI) side effects, such as diarrhea, nausea, vomiting, and abdominal pain. However, these side effects have not been evaluated in clinical trials in people with relapsing forms of MS.